NEW YORK (GenomeWeb) – B Braun Medical US and Tuebingen, Germany-based CeGaT today announced the launch of a US company offering next-generation sequencing-based diagnostics.
The new firm called B Braun CeGaT is based in B Braun Medical's headquarters in Bethlehem, Pa. and will offer CeGaT's diagnostic panels for evaluating all the genes that are associated with a patient's phenotype. The technology was launched in 2010 and is being made available in the US with the establishment of B Braun CeGaT.
According to CeGaT's website, it offers 159 diagnostic panels for cardiac disease, kidney disease, tumor syndromes, and other ailments. The panels are run on the Illumina HiSeq 2500 and MiSeq instruments, as well as Thermo Fisher Scientific's Ion Torrent Personal Genome Machine platforms.
"After many years of experience in the design, sequencing, and analysis of diagnostic panels in Germany, we can offer a real value and treatment decision support to the clinicians in the US," CeGaT Founder and CEO Dirk Biskup said in a statement.